admin – Page 2772 – Get News Story

From Content Creator to Solar Industry Leader: Dondre Frank Leverages Content Expertise to Scale Multi-Industry Ventures

Entrepreneur expands real estate and health optimization businesses while maintaining focus on scalable systems and family-driven mission.

Dondre Frank, a multi-industry entrepreneur, is expanding his ventures across real estate and health optimization, building on a 12-year marketing foundation that has fueled the launch and growth of Millennial Capital Group and NextGen Supply Clinic.

Frank’s journey began in content creation, producing and editing branded videos for companies aiming to grow their digital presence. His collaborations with seven-figure brands provided insight into consumer behavior and brand positioning, skills that later proved critical as he scaled sales teams and built operational systems across different sectors. “You don’t have to be great to start, you have to start to be great,” Frank said.

In 2020, Frank entered the solar industry, applying his branding and sales expertise to build and mentor high-performing sales teams. His strategic approach combined video-driven outreach and systemized sales materials that supported representatives in achieving six-figure earnings while driving installs and volume for the business. This success positioned him to leverage profits into launching Millennial Capital Group, his real estate investment firm.

Millennial Capital Group focuses on off-market properties, wholesaling, and creative deal structuring. Using digital lead generation and efficient operations, Frank has scaled the business into new markets while maintaining a lean approach that prioritizes profitability and sustainability. This aligns with his emphasis on long-term equity building for his family, linking each business milestone to a clear mission.

Driven by the growth of health optimization, Frank launched NextGen Supply Clinic to address gaps in clinic access to high-quality peptide therapies and regenerative health products. The platform helps med spas and clinics streamline sourcing while maintaining compliance and efficiency. Virtual teams, automated outreach, and a CRM-backed workflow allow NextGen Supply Clinic to manage growth while focusing on client outcomes. This strategy mirrors Frank’s broader business methodology of scalable systems backed by clear processes.

Under Frank’s leadership, both Millennial Capital Group and NextGen Supply Clinic have achieved revenue milestones that underscore his commitment to cross-industry scalability. Millennial Capital Group has expanded into key real estate markets in Texas and Florida, while NextGen Supply Clinic serves clinics across the Midwest and Southeastern United States, with plans to enter additional regional markets next year.

Frank’s operational philosophy is rooted in reinvestment and continuous learning. Profits are redirected into mentorship programs, process automation, and team development, ensuring each business operates efficiently while leaving room for innovation and growth. “You turn into what you tune into, and what entertains you, trains you,” Frank said.

Beyond business, Frank’s motivations are anchored in family responsibility. Raised in a household where he took on leadership early, he credits his mother, grandmother, and younger family members as his reason for building sustainable ventures that contribute to generational stability.

His personal brand, Unemployable Millionaire, reflects his commitment to creating a life where skill sets, ownership, and faith provide financial independence and personal agency. The brand serves as an educational and motivational platform for aspiring entrepreneurs, with Frank sharing insights from his journey to encourage others to pursue practical pathways to independence through skill development and business building.

Frank’s strategy across industries remains centered on leveraging his background in storytelling, system building, and sales leadership to identify opportunities, structure efficient processes, and scale effectively. His businesses operate with a clear mission: to build long-term assets that contribute to family stability and community opportunity while proving that consistent systems and intentional branding can drive measurable results across sectors.

Dondre Frank’s ongoing expansion of Millennial Capital Group and NextGen Supply Clinic demonstrates that foundational marketing expertise, combined with disciplined execution, can enable practical entrepreneurship across industries. His commitment to systems thinking and scalable processes offers a clear model for entrepreneurs looking to diversify and build sustainable businesses in today’s evolving economy.

Frank’s continued efforts underscore the importance of leveraging practical skills and disciplined planning while maintaining a clear purpose. As Millennial Capital Group expands its presence in new real estate markets and NextGen Supply Clinic grows its client base, Frank remains focused on building ventures that align with his family-centered values and scalable operational methods.

For updates on Dondre Frank’s ventures and educational content on business building, visit his LinkedIn and Instagram profiles at https://www.instagram.com/dondrefrank and https://www.instagram.com/unemployablemillionaire.

About Millennial Capital Group

Millennial Capital Group is a real estate investment firm founded by Dondre Frank, focusing on off-market acquisitions, creative deal structuring, and scalable operational systems. The company uses digital marketing and efficient processes to secure profitable deals and expand into new markets while prioritizing long-term equity for stakeholders.

About NextGen Supply Clinic

NextGen Supply Clinic, launched by Dondre Frank, serves med spas and health optimization clinics by providing streamlined access to high-quality peptide therapies and regenerative health products. The platform emphasizes compliance, efficiency, and client-focused solutions to help clinics improve service delivery while maintaining operational clarity as they expand into growth markets.

Media Contact
Contact Person: Dondre Frank
Email: Send Email
Country: United States
Website: https://www.linkedin.com/company/nextgensupplyclinic

Brands Forever has officially launched its digital platform

Brands Forever: List of Forever Top Brands of India.

Brands Forever has created BrandsForever.in to fight fraudulent reviews and make people more confident in finding brands online. It wants to give Indian consumers and businesses a clear, reputation-first listing system with OTP-verified user ratings, business validation, and editorial insights.

July 8, 2025 – Jaipur, India – Brands Forever has officially launched its digital platform, BrandsForever.in, in response to growing concerns about phoney reviews and altered online business profiles. The goal of the platform is to improve trust and transparency in India’s brand discovery ecosystem. On June 16, the platform went live. It has verified company listings, validated user reviews, and editorial insights that are meant to help people get a better idea of the businesses they do business with online.

Brands Forever, a company that helps Indian consumers get authentic business information, came up with the idea for the new platform. The platform’s goal is to set new standards for how businesses and customers engage online by fixing the many problems with trustworthiness that exist in the world of digital reviews.

Prashant Sharma, a representative for Brands Forever, stated, “Businesses too often either overpromise or fall victim to unfair misrepresentation. We’re building an ecosystem with BrandsForever where both businesses and customers can trust the information they see.”

A Platform Based on Proof

A multi-step verification process is at the heart of the platform. Before they can be included on BrandsForever.in, businesses have to go through document validation, operational checks, and sentiment screening. Also, all user reviews are verified with a one-time password (OTP) mechanism to make sure that real people are posting comments.

The platform’s rules clearly say that fake reviews and sponsored endorsements, which have been a problem in India’s digital marketplace for a long time, are not allowed. “We’ve put in place ways to stop manipulation at all levels,” Sharma said. “It’s not just about getting rid of the bad; it’s also about showing the good in a way that is fair, verifiable, and easy to understand.”

Not Just Star Ratings

The portal has both user-submitted reviews and editorial reviews produced by experts in the field. These reviews don’t only look at ratings; they also look at the customer experience, the quality of service, and how consistent the brand is. The company says that this two-tiered structure gives users a more fair view when they are looking up businesses online.

Sharma stated, “It’s like having a digital friend who has done all the work for you. We don’t just give you a star rating; we explain why that rating exists, what it means, and how it stacks up against other businesses in the same field.”

Each business profile has important information like hours of operation, contact information, links to social media, and multimedia features like images and videos of products. The program also lets you use Google Maps and get verified feedback from real clients.

Brands that serve both consumers and businesses equally Forever says that its objective has two parts: to help people make smart choices and to give honest businesses a place to show off their work.

Sharma added, “It’s about trust for customers. For businesses, it’s all about trust. BrandsForever.in is a trust engine that gives businesses a fair opportunity and gives consumers actual information.”

This idea of being open to everyone is shown in the design of the website. Its user interface is easy to use for people of all ages. It has easy-to-understand navigation, filters by category and area, and the option to bookmark or follow your favourite listings.

Moving Towards a Trustworthy Culture

It’s not just a product launch; Brand Forever is being marketed as the start of a bigger shift in Indian internet commerce that emphasises reputation over ranking and openness over techniques.

The firm has listed a few new features that will be available soon, such as:

• Public Q&A forums for customers

• Verified business response threads

• Editorial case studies and stories of customers that have been successful

• Ethical grading scales in addition to regular review scores

• Monthly lists of the best businesses in each industry

The company’s purpose is to create a community-driven model that encourages responsibility and honours service and quality that are always the same.

Timing is key

The platform’s introduction comes at a time when Indian shoppers are getting more picky. As more people shop and find services online, worries about false information, paid reviews, and inaccurate listings grow. Brands Forever thinks that the market is now ready for a platform that is based on openness.

The Indian market is growing up. People want to be smart with their money. Companies want to be found for the right reasons. “Brands Forever is our answer to both,” Sharma said.

Plans for Future Growth

At first, Brands Forever will only have verified listings in major Indian cities. The site will grow over time by adding new features in stages. One of the company’s top focusses in the near future is:

• Making apps for Android and iOS devices

• Rankings by sector, such as cafés, auto repair, education, and health care

• Adding video testimonials

• Connections to third-party APIs for extra data validation

Business owners can use custom dashboards to keep an eye on and manage their public reputation.

The platform also wants to work with professionals, communities, and organisations in the area to make its data verification process stronger and make sure that listings are always up to date and accurate.

About Brands Forever

Brands Forever is a company located in Jaipur that works to help people find trustworthy brands all around India. The goal of the organisation is to get rid of false information on the internet and make a place where businesses and consumers can talk to each other clearly and responsibly. Brands Forever wants to change how internet reputation is formed and measured by using technology, strict editing, and human verification.

Visit https://brandsforever.in for more information.

Media Contact
Company Name: Brands Forever
Contact Person: Prashant Sharma
Email: Send Email
Phone: +91-7976415312
Address:Crown Square Mall, Gandhipath Vaishali Nagar
City: Jaipur
State: Rajasthan – 302021
Country: India
Website: https://brandsforever.in/

The Catalytic Collective Announces Soft Launch and Opens Founding Membership for Women Seeking Purposeful Next Chapters

Philadelphia, PA – July 8, 2025 – The Catalytic Collective, an organization founded to support accomplished women executives, is pleased to announce the soft launch of its platform and the opening of its Founding Membership. Established by Sonya Weigle, a seasoned biotech and pharmaceutical executive, The Catalytic Collective is a community where women with decades of leadership experience can explore new purpose-driven ventures.

Sonya Weigle: Founder of The Catalytic Collective

The Collective was founded to meet a growing need among executive women at a career crossroads – those stepping out of long-held leadership roles, investing in emerging ventures, or building businesses that reflect their evolving passions. It aims to provide an intentional space for reflection, recalibration, and reinvention with a focus on community, purpose, and strategic support.

The Founding Membership will serve as the cornerstone of the community’s development. This brings together a select group of empowered women with more than 20 years of experience across diverse sectors. As the inaugural cohort, these members will help shape the future of the Collective while gaining access to exclusive offerings. They’ll participate in curated gatherings and opportunities for meaningful collaboration, going beyond transactional networking but toward deeper alignment and connections.

“This is unlike anything I’ve seen before,” said Annette, a new member of the Collective. “Many of these groups are just career-focused, just checking the boxes. The Catalytic Collective is well thought out and is dedicated and committed to executive women who are looking for inspiration and community to navigate their next chapters. The topics are motivating and inspiring and make us want to engage.”

The Catalytic Collective is built for those ready to move forward with intention and to do so in the company of peers who understand both the rewards and challenges of executive leadership.

With applications now open, the Collective invites interested leaders to explore the platform and learn more about its mission. From peer advisory circles to private events and facilitated strategy sessions, the Collective offers resources to support both personal fulfillment and professional evolution.

To learn more, please visit https://thecatalyticcollective.com.

About The Catalytic Collective

The Catalytic Collective exists to nurture and empower exceptional women leaders as they move towards the next extraordinary chapter of their lives. Through curated community and shared purpose, it supports members in turning their experience into impact on their terms.

Socials: Instagram, LinkedIn @thecatalyticcollective

Media Contact
Company Name: The Catalytic Collective
Contact Person: Coushatta Fuller
Email: Send Email
Phone: (214) 997-1223
Country: United States
Website: https://thecatalyticcollective.com/

Following Years of Anguish, Ceciley Maxa is Now Living Pain-Free After Groundbreaking CRPS Treatment from the Spero Clinic in Arkansas

For years, chronic condition CRPS caused Ceciley Maxa extreme pain, also leaving her disabled. After receiving innovative CRPS treatment from the Spero Clinic, Ceciley achieved long-awaited healing and relief.

Spraining your ankle may not sound like a big deal – it’s uncomfortable and painful, but recovery is usually quick and without complications. Yet, in some cases, a minor injury can spark off a condition that results in excruciating chronic pain and loss of mobility. This condition is called Complex Regional Pain Syndrome, or CRPS.

For Ceciley Maxa, a lively 25-year-old from River Falls, Wisconsin, her sprained ankle developed into years of living a nightmare, until she couldn’t take it any longer. “The sensation can be described as being burned with a blowtorch on the skin,” she said.

After navigating hospitals, clinics, and doctors without remission, Ceciley eventually found The Spero Clinic in Arkansas, which specializes in holistic treatments for neurologic disorders, including CRPS.

The Scourge of CRPS

Among the many neurologic dysfunction disorders, CRPS is the most brutal. More than 200,000 people in the country suffer from this disorder, which, according to the medical community, cannot be cured. Patients are being sent home with pain medications, which may bring temporary relief but also create long-term dependencies and damaging effects.

CRPS is associated with imbalance and malfunction of the autonomic nervous system, resulting in disability, chronic pain, and functional loss. It can present itself in several stages, ranging from intense, burning pain to permanent changes in the skin and bones.

For Ceciley, this meant enduring bouts of nearly unbearable, panic-inducing pain. Unable to work and missing out on planning her 2018 wedding, she said, “I wasn’t able to live a normal life with my friends or family,” she says.

Healing the “Impossible”

Given its many alarming symptoms, CRPS is considered an “impossible” disorder. However, The Spero Clinic Founder and CEO, Dr. Katinka van der Merwe, does not agree. In her words, “I have made it my life’s mission to treat patients who suffer from so-called ‘impossible’ diseases – those that have been given up by the medical community.”

Spero’s focus is on isolating and repairing the global failure of the central nervous system, which is causing the extreme body phenomena linked to neurologic dysfunction disorders. Within that system, the Vagus nerve is a major player in solving the puzzle that forms CRPS.

Spero’s treatment protocol, therefore, consists of calming the Vagus nerve and central nervous system, and restoring these crucial systems to function optimally again.

New Hope and A New Future

For CRPS patient Ceciley, treatment with The Spero Clinic has given her something crucial: full remission and a pain-free life. “It has helped more than anything I have experienced.”

Says Dr. Katinka, “Our whole focus with everything we do in here is to remove anything that’s blocking the central nervous system from doing its job.” For the hundreds of other Spero patients suffering from CRPS, that focus has meant a new future – a new life.

For more information about the Spero Clinic, please call (479) 304-8202.

Video Link: https://www.youtube.com/embed/FZMZC0X5pEY

Media Contact
Company Name: The Spero Clinic
Contact Person: Kaylie Crane
Email: Send Email
Phone: 4794820080
Address:22 Colt Square Dr
City: Fayetteville
State: Arkansas
Country: United States
Website: www.thesperoclinic.com

Hepatitis D Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Eiger BioPharma, Gilead Sciences, Shanghai HEP Pharma, Hepatera Ltd. Vir Biotech, Ribocure Pharm

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hepatitis D pipeline constitutes 8+ key companies continuously working towards developing 10+ Hepatitis D treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Hepatitis D Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hepatitis D Market.

The Hepatitis D Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hepatitis D Pipeline Report:

Companies across the globe are diligently working toward developing novel Hepatitis D treatment therapies with a considerable amount of success over the years.
Hepatitis D companies working in the treatment market are Eiger BioPharmaceuticals, Gilead Sciences, Shanghai HEP Pharmaceutical, Hepatera Ltd. Vir Biotechnology, Inc., Soroka University Medical Center, Ribocure Pharmaceuticals AB, Janssen Research & Development, Hoffmann-La Roche, Hepatera Ltd, and others, are developing therapies for the Hepatitis D treatment

Emerging Hepatitis D therapies in the different phases of clinical trials are- lonafarnib, Bulevirtide, Hepalatide, PEG IFN alfa-2a, VIR-2218, Lonafarnib, RBD1016, JNJ-73763989, peginterferon alfa-2a [Pegasys], Myrcludex B, and others are expected to have a significant impact on the Hepatitis D market in the coming years.
In May 2025, In a Phase II trial (NCT05461170) for hepatitis D, Vir Biotechnology’s combination therapy demonstrated promising results, with all six patients achieving a sustained virologic response at their last visit. Additionally, every patient showed either hepatitis D virus RNA levels below the limit of detection (LOD) or a reduction of at least 2 log10 IU/mL from baseline.
In March 2025, The first patient was enrolled in ECLIPSE 1, a Phase 3 clinical trial evaluating Vir Biotechnology’s investigational combination of tobevibart and elebsiran in adults with chronic hepatitis D. This trial marks the start of the Phase 3 ECLIPSE program, which, if successful, is expected to support regulatory submissions for the approval of this dual therapy for hepatitis D (hepatitis delta). ECLIPSE 1 aims to enroll up to 120 participants across the U.S. and selected regions outside Europe, with an additional Phase 3 study, ECLIPSE 2, planned to further advance this effort.
In January 2025, The U.S. FDA granted Breakthrough Therapy designation to brelovitug, an investigational hepatitis D treatment from Bluejay Therapeutics. This designation is given to therapies that show significant potential in addressing serious conditions and demonstrate promising results in early clinical trials. It aims to accelerate the development and approval process, ensuring patients gain faster access to innovative treatments.
In December 2024, Vir Biotechnology’s experimental treatment combination, tobevibart and elebsiran, for chronic hepatitis D has received Breakthrough Therapy designation from the U.S. FDA and PRIME designation from the European Medicines Agency (EMA).
In November 2024, Vir Biotechnology, Inc. (NASDAQ: VIR) announced positive findings from the SOLSTICE Phase 2 trial assessing tobevibart, alone or with elebsiran, in individuals with chronic hepatitis delta (CHD). This investigational monoclonal antibody and siRNA combination, dosed monthly, achieved a 100% virologic response with rapid suppression of hepatitis delta virus (HDV) RNA. By Week 24, 41% (13/32) of participants had HDV RNA below the lower limit of quantification (LLOQ) with target not detected (TND), increasing to 64% (14/22) by Week 36. Among those who reached Week 60, 80% (4/5) achieved HDV RNA TND, demonstrating promising antiviral activity.

Hepatitis D Overview

Hepatitis D, also known as hepatitis delta, is a liver infection caused by the hepatitis D virus (HDV). It is a defective virus that requires the presence of hepatitis B virus (HBV) to replicate. Hepatitis D is transmitted through contact with infected blood or bodily fluids, often occurring in individuals already infected with HBV. It can lead to severe liver disease, including cirrhosis and liver failure. The infection is more aggressive than HBV alone, with a higher risk of complications. Currently, there is no specific antiviral treatment, but HBV vaccination can help prevent hepatitis D infection.

Get a Free Sample PDF Report to know more about Hepatitis D Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight

Emerging Hepatitis D Drugs Under Different Phases of Clinical Development Include:

lonafarnib: Eiger BioPharmaceuticals
Bulevirtide: Gilead Sciences
Hepalatide: Shanghai HEP Pharmaceutical
PEG IFN alfa-2a: Hepatera Ltd.
lonafarnib: Eiger BioPharmaceuticals
VIR-2218: Vir Biotechnology, Inc.
Lonafarnib: Soroka University Medical Center
RBD1016: Ribocure Pharmaceuticals AB
JNJ-73763989: Janssen Research & Development
peginterferon alfa-2a [Pegasys]: Hoffmann-La Roche
Myrcludex B: Hepatera Ltd

Hepatitis D Route of Administration

Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Hepatitis D Molecule Type

Hepatitis D Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Hepatitis D Pipeline Therapeutics Assessment

Hepatitis D Assessment by Product Type
Hepatitis D By Stage and Product Type
Hepatitis D Assessment by Route of Administration
Hepatitis D By Stage and Route of Administration
Hepatitis D Assessment by Molecule Type
Hepatitis D by Stage and Molecule Type

DelveInsight’s Hepatitis D Report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Hepatitis D product details are provided in the report. Download the Hepatitis D pipeline report to learn more about the emerging Hepatitis D therapies

Some of the key companies in the Hepatitis D Therapeutics Market include:

Key companies developing therapies for Hepatitis D are – Pharma Essentia, REPLICor, SomaGenics, Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, Vir Biotechnology, VLP Biotech, and others.

Hepatitis D Pipeline Analysis:

The Hepatitis D pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis D with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis D Treatment.
Hepatitis D key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hepatitis D Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis D market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hepatitis D drugs and therapies

Hepatitis D Pipeline Market Drivers

Rising Prevalence of Hepatitis D, Advancements in Antiviral Therapies, Growing Awareness and Screening Programs, Government and Non-Profit Support, Emerging Targeted Therapies, Strategic Collaborations and Investments, are some of the important factors that are fueling the Hepatitis D Market.

Hepatitis D Pipeline Market Barriers

However, Limited Treatment Options, High Cost of Therapies, Low Awareness and Diagnosis Rates, Regulatory Challenges, Co-infection with HBV Challenges, Limited Access to Healthcare in Developing Regions, and other factors are creating obstacles in the Hepatitis D Market growth.

Scope of Hepatitis D Pipeline Drug Insight

Coverage: Global
Key Hepatitis D Companies: Eiger BioPharmaceuticals, Gilead Sciences, Shanghai HEP Pharmaceutical, Hepatera Ltd. Vir Biotechnology, Inc., Soroka University Medical Center, Ribocure Pharmaceuticals AB, Janssen Research & Development, Hoffmann-La Roche, Hepatera Ltd, and others
Key Hepatitis D Therapies: lonafarnib, Bulevirtide, Hepalatide, PEG IFN alfa-2a, VIR-2218, Lonafarnib, RBD1016, JNJ-73763989, peginterferon alfa-2a [Pegasys], Myrcludex B, and others
Hepatitis D Therapeutic Assessment: Hepatitis D current marketed and Hepatitis D emerging therapies
Hepatitis D Market Dynamics: Hepatitis D market drivers and Hepatitis D market barriers

Request for Sample PDF Report for Hepatitis D Pipeline Assessment and clinical trials

Table of Contents

1. Hepatitis D Report Introduction

2. Hepatitis D Executive Summary

3. Hepatitis D Overview

4. Hepatitis D- Analytical Perspective In-depth Commercial Assessment

5. Hepatitis D Pipeline Therapeutics

6. Hepatitis D Late Stage Products (Phase II/III)

7. Hepatitis D Mid Stage Products (Phase II)

8. Hepatitis D Early Stage Products (Phase I)

9. Hepatitis D Preclinical Stage Products

10. Hepatitis D Therapeutics Assessment

11. Hepatitis D Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hepatitis D Key Companies

14. Hepatitis D Key Products

15. Hepatitis D Unmet Needs

16 . Hepatitis D Market Drivers and Barriers

17. Hepatitis D Future Perspectives and Conclusion

18. Hepatitis D Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatitis D Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Eiger BioPharma, Gilead Sciences, Shanghai HEP Pharma, Hepatera Ltd. Vir Biotech, Ribocure Pharm

Hepatitis C Virus Infection Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dongguan HEC TaiGen Biopharma, Cocrystal Pharma, Abbvie, Janssen

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hepatitis C Virus Infection pipeline constitutes 20+ key companies continuously working towards developing 20+ Hepatitis C Virus Infection treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Hepatitis C Virus Infection Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hepatitis C Virus Infection Market.

The Hepatitis C Virus Infection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hepatitis C Virus Infection Pipeline Report:

Companies across the globe are diligently working toward developing novel Hepatitis C Virus Infection treatment therapies with a considerable amount of success over the years.
Hepatitis C Virus Infection companies working in the treatment market are Dongguan HEC TaiGen Biopharmaceuticals, Cocrystal Pharma, Abbvie, Janssen Infectious Diseases, Gilead Sciences, Merck Sharp & Dohme LLC, Bristol-Myers Squibb, and others, are developing therapies for the Hepatitis C Virus Infection treatment

Emerging Hepatitis C Virus Infection therapies in the different phases of clinical trials are- TG-2349, CC-31244, Glecaprevir/Pibrentasvir (GLE/PIB), Simeprevir, LDV/SOF, EBR/GZR (50 mg/100 mg) FDC, Daclatasvir, and others are expected to have a significant impact on the Hepatitis C Virus Infection market in the coming years.
In April 2025, Boston-based Atea Pharmaceuticals announced the dosing of the first patient in its C-BEYOND Phase 3 trial, being conducted in the US and Canada. This study will assess the effectiveness of the combination of bemnifosbuvir and ruzasvir in adults with chronic hepatitis C virus (HCV), comparing it to the standard treatment regimen of sofosbuvir and velpatasvir. The company stated, “Enrolling our first patient in this global Phase 3 program marks a significant step forward in our efforts to develop a differentiated, next-generation therapy for HCV.”
In March 2025, Atea Pharmaceuticals is preparing to initiate two parallel Phase 3 clinical trials to evaluate its investigational combination of bemnifosbuvir and ruzasvir in individuals with hepatitis C. One trial will be conducted in the U.S. and Canada, while the other will enroll participants at sites outside North America. Both studies will compare the experimental therapy to the approved hepatitis C treatment Epclusa (sofosbuvir/velpatasvir). Patient recruitment is expected to begin in April. These plans follow positive discussions with the U.S. Food and Drug Administration (FDA) in January, where encouraging results from a Phase 2 trial (NCT05904470) were reviewed.
In July 2024, The World Health Organization (WHO) has prequalified the first self-test for hepatitis C, a liver disease caused by the hepatitis C virus (HCV). HCV can lead to acute or chronic hepatitis, with symptoms ranging from mild illness to severe, lifelong conditions such as liver cancer and cirrhosis. The virus is bloodborne, and transmission often occurs through unsafe injection practices, inadequate healthcare procedures, blood transfusions, injection drug use, or contact involving blood exposure. Although no vaccine exists for HCV, antiviral treatments can effectively cure 95% of infections.

Hepatitis C Virus Infection Overview

Hepatitis C Virus (HCV) Infection is a liver disease caused by the hepatitis C virus. It spreads primarily through exposure to infected blood, often via shared needles, unscreened blood transfusions, or unsterilized medical equipment. HCV infection can be acute (short-term) or chronic (long-term). While acute cases may resolve spontaneously, chronic infection can lead to severe complications like liver fibrosis, cirrhosis, and liver cancer.

Get a Free Sample PDF Report to know more about Hepatitis C Virus Infection Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hepatitis-c-virus-infection-pipeline-insight

Emerging Hepatitis C Virus Infection Drugs Under Different Phases of Clinical Development Include:

TG-2349: Dongguan HEC TaiGen Biopharmaceuticals
CC-31244: Cocrystal Pharma
Glecaprevir/Pibrentasvir (GLE/PIB): Abbvie
Simeprevir: Janssen Infectious Diseases
LDV/SOF: Gilead Sciences
EBR/GZR (50 mg/100 mg) FDC: Merck Sharp & Dohme LLC
Daclatasvir: Bristol-Myers Squibb

Hepatitis C Virus Infection Route of Administration

Hepatitis C Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Hepatitis C Virus Infection Molecule Type

Hepatitis C Virus Infection Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Hepatitis C Virus Infection Pipeline Therapeutics Assessment

Hepatitis C Virus Infection Assessment by Product Type
Hepatitis C Virus Infection By Stage and Product Type
Hepatitis C Virus Infection Assessment by Route of Administration
Hepatitis C Virus Infection By Stage and Route of Administration
Hepatitis C Virus Infection Assessment by Molecule Type
Hepatitis C Virus Infection by Stage and Molecule Type

DelveInsight’s Hepatitis C Virus Infection Report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Hepatitis C Virus Infection product details are provided in the report. Download the Hepatitis C Virus Infection pipeline report to learn more about the emerging Hepatitis C Virus Infection therapies

Some of the key companies in the Hepatitis C Virus Infection Therapeutics Market include:

Key companies developing therapies for Hepatitis C Virus Infection are – Sunshine Lake Pharma Co., Ltd., GeneCure Biotechnologies, Biotron, Cocrystal Pharma, Genecure Biotechnologies Preclinical, iQur, Atea Pharmaceutical, Dongguan HEC TaiGen Biopharmaceuticals, Nanjing Sanhome Pharmaceutical, and others.

Hepatitis C Virus Infection Pipeline Analysis:

The Hepatitis C Virus Infection pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis C Virus Infection with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis C Virus Infection Treatment.
Hepatitis C Virus Infection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hepatitis C Virus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis C Virus Infection market.

Download Sample PDF Report to know more about Hepatitis C Virus Infection drugs and therapies

Hepatitis C Virus Infection Pipeline Market Drivers

Rising Prevalence of HCV, Advancements in Antiviral Therapies, Global Health Initiatives, Improved Diagnostic Tools, Focus on Pan-genotypic Treatments, are some of the important factors that are fueling the Hepatitis C Virus Infection Market.

Hepatitis C Virus Infection Pipeline Market Barriers

However, High Treatment Costs, Lack of Vaccine, Asymptomatic Cases, Drug Resistance, Healthcare Infrastructure Gaps, and other factors are creating obstacles in the Hepatitis C Virus Infection Market growth.

Scope of Hepatitis C Virus Infection Pipeline Drug Insight

Coverage: Global
Key Hepatitis C Virus Infection Companies: Dongguan HEC TaiGen Biopharmaceuticals, Cocrystal Pharma, Abbvie, Janssen Infectious Diseases, Gilead Sciences, Merck Sharp & Dohme LLC, Bristol-Myers Squibb, and others
Key Hepatitis C Virus Infection Therapies: TG-2349, CC-31244, Glecaprevir/Pibrentasvir (GLE/PIB), Simeprevir, LDV/SOF, EBR/GZR (50 mg/100 mg) FDC, Daclatasvir, and others
Hepatitis C Virus Infection Therapeutic Assessment: Hepatitis C Virus Infection current marketed and Hepatitis C Virus Infection emerging therapies
Hepatitis C Virus Infection Market Dynamics: Hepatitis C Virus Infection market drivers and Hepatitis C Virus Infection market barriers

Request for Sample PDF Report for Hepatitis C Virus Infection Pipeline Assessment and clinical trials

Table of Contents

1. Hepatitis C Virus Infection Report Introduction

2. Hepatitis C Virus Infection Executive Summary

3. Hepatitis C Virus Infection Overview

4. Hepatitis C Virus Infection- Analytical Perspective In-depth Commercial Assessment

5. Hepatitis C Virus Infection Pipeline Therapeutics

6. Hepatitis C Virus Infection Late Stage Products (Phase II/III)

7. Hepatitis C Virus Infection Mid Stage Products (Phase II)

8. Hepatitis C Virus Infection Early Stage Products (Phase I)

9. Hepatitis C Virus Infection Preclinical Stage Products

10. Hepatitis C Virus Infection Therapeutics Assessment

11. Hepatitis C Virus Infection Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hepatitis C Virus Infection Key Companies

14. Hepatitis C Virus Infection Key Products

15. Hepatitis C Virus Infection Unmet Needs

16 . Hepatitis C Virus Infection Market Drivers and Barriers

17. Hepatitis C Virus Infection Future Perspectives and Conclusion

18. Hepatitis C Virus Infection Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatitis C Virus Infection Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dongguan HEC TaiGen Biopharma, Cocrystal Pharma, Abbvie, Janssen

Tesla Fleet App Revolution: FleetBold Is Redefining Multi-Car Management

Managing multiple Teslas or a mix of Teslas and other vehicles is no longer a challenge limited to tech-savvy developers or overpriced platforms. FleetBold was designed from the ground up to serve the real needs of Tesla fleet owners, Turo Hosts, rental operators, and families with more than one Tesla, the platform offers hardware-free functionality at a cost-effective rate.

FleetBold distinguishes itself as a purpose-built platform that supports all major vehicle brands, while advancing Tesla telemetrics to enable scalable and streamlined fleet management, while taking Tesla telemetrics to the next level making it the Tesla Fleet App built for scale and simplicity.

Why FleetBold Is the Tesla Fleet App That Works With All Vehicle Types

Unlike platforms limited to EVs or a specific brand, FleetBold is designed to work with all types of vehicles electric, hybrid, or gas-powered. Whether a rental operator is managing a large fleet or tracking multiple family vehicles, FleetBold keeps everything unified.

It also supports integrations with third-party GPS devices like Bouncie, One Step GPS, and others giving rental operators and growing businesses the flexibility to expand without switching tools or adding complexity.

A Tesla Fleet App Engineered for Real-Time Data and Multi-Car Visibility

FleetBold developed its own internal Tesla API, allowing real-time vehicle data to stream directly into the platform without third-party gateways. This results in a faster, smoother, and more complete experience than other competitors.

FleetBold outperforms popular Tesla fleet apps by offering true real-time tracking, multi-car visibility on a single map, and detailed Supercharging analytics all without the need for external hardware. It’s the Tesla Fleet App designed for those who manage Teslas at scale and need a reliable, unified platform.

Users can review Tesla Supercharging history (including charge received, session times, and locations), access trip route history, and soon predictive route analysis based on historical behavior.

How This Tesla Fleet App Supports Scaling From 10 to 1 Million Users

FleetBold was engineered over two years with scalability in mind. Its internal modules are fully auto-scalable, meaning that whether 10 or 1 million users access the platform simultaneously, performance remains consistent. This makes it the ideal tool not just for small operators, but for large-scale rental businesses and national fleets.

FleetBold Features That Turo Hosts and Tesla Fleet Owners Actually Use

FleetBold includes a range of practical features designed to address daily operational challenges in fleet management. Its DTC Assistant interprets diagnostic trouble codes from both Tesla and non-Tesla vehicles, providing actionable insights to simplify maintenance. The platform also offers mileage tracking capabilities, which are especially useful for professionals who require accurate records for tax or reimbursement purposes. Smart alerts notify operators of critical events such as low battery levels, delayed returns, or disconnected vehicles, enabling timely responses and improved oversight across the fleet.

Affordable by Design

FleetBold’s pricing model is spot-based; users pay only for the number of vehicles connected. Plans start at $9.99/month per spot, with premium features available up to $19.99/month. Enterprise plans are available for larger fleets with custom needs, making FleetBold both scalable and cost-effective.

More Than a Tracker A Platform Built for What’s Next

FleetBold’s roadmap includes expanded analytics, new GPS integrations, CRM tools, and even insurance partnerships, aiming to evolve into a complete operational ecosystem for mobility-focused industries.

Fleet operators managing multiple Teslas, working in rentals, or seeking better control over the fleet without costly hardware or complicated setups just need to visit www.fleetbold.com.

Tesla accounts can be connected instantly to gain full operational control without hardware, delays, or technical hurdles.

Media Contact
Company Name: FleetBold
Contact Person: Team
Email: Send Email
Country: United States
Website: https://www.fleetbold.com/

Terry Register – CEO of Capsur Tax and Estate Planning Interviewed on the Influential Entrepreneurs Podcast, Discussing Tax Mitigation Strategies for Business Owners

Terry Register Discusses Mastering Tax Mitigation Strategies for Business Owners

Listen to the interview on the Business Innovators Radio Network: Interview with Terry Register- CEO of Capsur Tax and Estate Planning- Tax Mitigation Strategies for Business Owners – Business Innovators Radio Network

In this episode of Influential Entrepreneurs, host Mike Saunders welcomes back Terry Register, CEO of Capsur Tax and Estate Planning, to discuss tax mitigation strategies for business owners. Terry emphasizes the importance of understanding tax planning and shares insights on common mistakes that successful entrepreneurs make. He highlights the significance of maximizing retirement contributions and encourages listeners to be proactive in their tax strategies. With a focus on foundational ideas, this episode serves as a valuable resource for business owners looking to enhance their financial planning and avoid costly pitfalls.

Business owners often underestimate the significance of maximizing their retirement contributions, resulting in missed opportunities for tax benefits and long-term financial growth. It is essential to understand the various retirement plans available, such as mega Roth IRAs and cash balance plans, to effectively mitigate taxes and accumulate wealth.

Many business owners fail to contribute adequately to their retirement plans. Some may only contribute enough to meet employee benefit requirements, while others may not contribute at all, thereby missing out on valuable tax advantages. Terry Register emphasizes that maximizing retirement contributions is a crucial strategy for business owners, not only to secure their financial future but also to enhance employee retention and satisfaction.

One of the standout options for retirement savings is the mega Roth IRA. This strategy allows individuals to contribute significantly more than traditional Roth IRAs, depending on their income and age. For example, individuals exceeding a certain income threshold can contribute up to $170,000 per year into a mega Roth IRA. The benefits of this strategy include:

Tax-Free Growth: Contributions grow tax-free, and qualified withdrawals after age 59½ are also tax-free, provided the account has been open for at least five years.
High Contribution Limits: The ability to contribute large sums can significantly enhance retirement savings, especially for high-income earners.

However, many business owners are unaware of this option or do not fully understand how to implement it effectively, leading to the underutilization of a powerful retirement savings tool.

Another effective retirement strategy is the cash balance plan, a type of defined benefit plan. This plan is particularly advantageous for business owners earning over $400,000 a year. The cash balance plan allows for substantial contributions based on age and income, providing a structured way to save for retirement while enjoying tax benefits. Key features include:

Defined Benefits: Unlike traditional retirement plans that depend on investment performance, cash balance plans offer a guaranteed benefit at retirement, appealing to business owners seeking stability.
Tax Deductibility: Contributions to cash balance plans are tax-deductible, significantly reducing taxable income for the business owner.

By strategically utilizing these retirement plans, business owners can secure their financial future while creating a more attractive benefits package for employees, thereby enhancing retention and overall business performance.

Terry shared: “We serve as a trusted partner to closely held businesses—delivering smart, personalized planning that helps reduce taxes, retain key employees, and preserve wealth across generations.”

Video Link: https://www.youtube.com/embed/EhQe1a3uq5k

About Terry Register

As President of Capsur Tax and Estate Planning, Terry Register leads with a clear and focused mission: to help business owners, high-income professionals, high-net-worth individuals, and closely held corporations navigate the complexities of tax planning, retirement strategy, estate structuring, and legacy preservation. Through personalized service and strategic insight, Terry delivers solutions designed to build long-term financial confidence and multigenerational impact.

Terry began his distinguished career at Fidelity Union, earning “Rookie of the Year” honors and qualifying for the Million Dollar Round Table (MDRT) in his first year. He later joined American Defender Life, where he consistently ranked among the top ten producers nationwide and earned annual recognition in the President’s Cabinet.

He founded Capsur with a vision to offer programs and planning strategies that empower individuals and businesses to reach their financial, retirement, and legacy goals. Today, he continues to work collaboratively with professionals and clients across the country on high-value joint cases that demand tailored and sophisticated solutions.

Terry’s leadership and production achievements have earned him national recognition, but his commitment to service goes beyond the business world. He has served as a trustee on the Endowment Committee at the University of North Carolina at Pembroke, a Corporate Board Member for G.R.A.C.E. Christian School in Raleigh, and an active supporter of charitable missions, including the Fellowship of Christian Athletes, the Zachary Taylor Orphanage in Kenya, and Uttermost Ministries.

A devoted husband, father, and grandfather, Terry resides in Raleigh, NC, with his wife. He is a longtime member of Bayleaf Baptist Church, where he has served on the Personnel Committee and continues to invest in his faith and community.

Learn more: https://www.capsurtaxandestateplanning.com/

Recent Interviews and News:

Terry Register Discusses Mastering Tax Strategies for Retirement: Terry Register- CEO of Capsur Tax and Estate Planning Interviewed on The Influential Entrepreneurs Podcast, Discussing Mastering Tax Strategies for Retirement – Authority Press Wire

Media Contact
Company Name: Marketing Huddle, LLC
Contact Person: Mike Saunders, MBA
Email: Send Email
Phone: 7202323112
Country: United States
Website: https://www.AuthorityPositioningCoach.com

Adventurous Oxfordshire Mum Shows Others How to Overcome Adversity in Debut Book

“Stronger Than the Storm: One Woman’s Journey of Adventure, Adversity and Unbreakable Spirit” by Felicity Ashley is published on 8th July 2025.

Motivational speaker Felicity Ashley is showing others what is possible when you do not give into fear, self-doubt or the belief that you are not strong enough, in her debut book.

In “Stronger Than the Storm,” the mum of three from Benson, Oxfordshire shares her powerful and deeply personal story of overcoming life’s biggest challenges. From a hip replacement in her early forties to rowing three-thousand miles across the Atlantic to facing cancer head-on and thriving.

Through each chapter, she shows how anyone can achieve extraordinary things and how some of the toughest moments in life can be turned into your purpose.

The inspiring account will encourage you to silence your inner critic, rewrite your story and stand tall in the face of life’s fiercest trials.

“Stronger Than the Storm” will immerse you in Felicity’s life lessons from the raw reality of navigating illness, grief, and uncertainty to the unexpected joy and simplicity of life at sea and the courage it takes to keep moving forward when nothing goes to plan.

Author Felicity Ashley says, “Stronger Than the Storm is a way for me to take my learnings from the trials and tribulations I’ve faced. It also provides hope for those reading it by showing there is always quiet strength to be found in community, humour and choosing to show up. And above all else, there are always moments of grace that shine through even the darkest storms because anything is possible.”

Felicity’s story is an honest look at what it means to face fear with open arms, keep moving forward when grief feels unbearable and find glimmers of hope even in the darkest hours.

Her extraordinary journey will move and inspire anyone who’s ever wondered, ‘Can I really get through this?’ Because sometimes, it is not about bouncing back. It’s about rising stronger than the storm.

Buy your copy of “Stronger Than the Storm” on Amazon: https://www.amazon.co.uk/dp/1068489103

For more information or interviews with Felicity Ashley, contact Nicola Rowley on 07932 656685 or email: nicola@njrpr.com

Media Contact
Company Name: TMSP Agency
Contact Person: Mark Stephen Pooler
Email: Send Email
Phone: +447930691683
Country: United Kingdom
Website: https://contactmark.me

Rod Chamberlin’s Latest Book Titled “Beyond Exit Planning” on Amazon Flash Sale

Business owners looking to exit on top and reimagine life after business have a golden opportunity—Rod Chamberlin’s new book, “Beyond Exit Planning: How to Create a Life-Changing New Chapter After Business,” is available now during a special Amazon Flash Sale for a limited time only.

Beyond Exit Planning delivers the tools, insights, and real-world strategies necessary to transform your business legacy into a launchpad for your next great adventure.

“With over 30 years helping entrepreneurs navigate their financial futures, I’ve seen how emotionally and financially complex exiting a business can be,” said author Rod Chamberlin. “This book is here to make sure no business owner has to face that uncertainty alone.”

The book walks readers through:

How to safeguard your legacy and avoid the most common—and costly—exit mistakes
What to do before the sale to maximize value and reduce taxes
Why a business without a plan risks disappearing into thin air
How to find purpose and fulfillment in life after business
What buyers are really looking for when evaluating your company

Rod’s compassionate guidance includes personal stories, expert interviews, and step-by-step frameworks that empower owners to leave on their terms and enter their next phase of life with clarity and confidence.

“This isn’t just about selling your business,” Chamberlin explains. “It’s about redefining what success looks like for you after the sale and building a life that’s as intentional as the business you built.”

Don’t miss the chance to grab “Beyond Exit Planning” at its lowest price ever during the limited-time Amazon Flash Sale. Whether you’re five years out or five months away, this is the roadmap every entrepreneur needs to exit right and move forward boldly.

Get your copy on special flash sale July 10, 2025.

https://www.amazon.com/dp/B0FDLCZT8V

About the Author

Rod Chamberlin has been an entrepreneur since age 10 and a trusted Financial Advisor since 1991. He holds a Master’s in Financial Services (MSFS) and multiple professional designations, including Certified Exit Planning Advisor (CEPA), Certified Mutual Fund Specialist (CFS), Retirement Income Specialist (RIS), Certified Annuity Specialist (CAS), Certified Estate Planning Specialist (CES), and Certified Tax Specialist (CTS).

Rod specializes in helping business owners maximize the value of their life’s work and transition successfully to the next chapter. Raised with strong Midwest values, Rod now lives in California, where he enjoys woodworking, welding, long-range shooting competitions, and spending time with his wife, Lora, and their daughters, Sara and Rachel.

Media Contact
Company Name: Imperial Action
Contact Person: Media Manager
Email: Send Email
Phone: (630) 923-5425
Country: United States
Website: http://imperialaction.com